Baird downgraded Vor Bio (VOR) to Neutral from Outperform with a price target of 25c, down from $14, after the company announced plans to wind down its clinical and manufacturing operations, beginning immediately, and pivot to looking for strategic alternatives for the business. The update led Baird to downgrade the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: